Simulations Plus, Inc. announced that the U.S. FDA has renewed its licenses to the DILIsym software platform. DILIsym is the industry gold standard for quantitative systems toxicology software.
Shares of Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) gapped up before the market opened on Thursday following a better than expected earnings announcement. The stock had previously closed at $38.46, but opened at $44.91. Simulations Plus shares last traded at $46.28, with a volume of 95,888 shares changing hands. The technology company reported […]
Total revenue of $18.3 million and diluted earnings per share of $0.20
Maintains full-year revenue guidance of $66 to $69 million and EPS guidance of $0.66 to $0.68
.